Skip to content

Effect of 12-week Probiotic Consumption Immobilized on Oat Flakes on Blood and Urine Biomarkers and Human Microbiome

Effect of Daily Lactococcus Cremoris Spp. Consumption Immobilized in Oat Flakes on Blood and Urine Biomarkers and Human Microbiome: a Randomized Placebo-controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06293859
Acronym
FOODBIOMES CT2
Enrollment
54
Registered
2024-03-05
Start date
2023-02-15
Completion date
2023-07-30
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this clinical trial was to evaluate the effects Lactococcus cremoris spp. im-mobilized on oat flakes on human microbiome and blood and urine biomarkers of associated with human health.

Detailed description

All eligible and consenting individuals were assigned a unique code for identification purposes. They were then randomly assigned to either the probiotic or placebo group. The probiotic group received oat flakes containing immobilized Lactococcus cremoris, while the placebo group received oat flakes indistinguishable in color, smell, and taste from the flakes with immobilized probiotics.Participants received written instructions on storing the product, which required refrigeration. They were instructed to consume 5 g of oats daily with a meal, ensuring the meal's temperature remained below 35 °C and was non-acidic (e.g., with yogurt). Biological samples were collected at three time points; before intervention, at 6th and 12th week.

Interventions

OTHERProbiotic oat flakes

2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes

OTHERConventional oat flakes

Commercial oat flakes

Sponsors

Democritus University of Thrace
CollaboratorOTHER
University of the Aegean
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* participants to be aged between 18 and 65 years * clinically tested with fasting plasma glucose less than 100 mg/dL * clinically tested withcholesterol less than 220 mg/dL * otherwise healthy

Exclusion criteria

* body mass index \[BMI\] higher than 40 kg/m2 (morbidly obese) * following a diet plan for weight loss * following a contraceptive treatment or taking probiotic supplements * following medication with an effect on lipaemia or glycemia indicators * having any allergies/intolerances to trial ingredients * pregnant or planning to become pregnant or breast feeding * users of illicit drug, having a chronic alcoholism or total daily alcohol intake more than 50 g per day * diagnosed with a chronic condition (cancer, active liver disease, severe kidney dysfunction, severe stroke in the last six months and conditions associated with an increased risk of bleeding) or any other serious medical condition that may affect the individual's ability to participate in a dietary intervention study * considered unreliable by the researcher or having a shorter life expectancy than the expected duration of the study due to some illness or if they were in any situation in which by the researcher's opinion their participation in the study was not considered safe (e.g. drug addiction, alcohol abuse).

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory biomarkersBlood samples were collected by venipuncture at three time points; before intervention, at 6th and 12th weekChange from baseline of hs-CRP and IL-6

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026